Oscotec Inc.

Genosco

Yuhan Corporation

Ho-Juhn Song

Jong Sung Koh

Jaekyoo Lee

In Y Lee

Se-Won Kim

Jang-Sik Choi

Jaesang Lee

Jung-ho Kim

Jung-Ho Kim

Byung-Chul Suh

Hong Woo Kim

Paresh Salgaonkar

Hee Kyu Lee

Dong Sik Jung

Sunhwa Chang

Hae-Jun Hwang

Youngsam Kim

Sun-Hee Lim

Se Ryung Kim

Dong-Sik Jung

Se Won Kim

Sung-Ho Park

Yung-Geun Choi

Yung-geun Choi

Ik-hwan Han

Tae-Im Lee

Eunho Lee

Tae-im Lee

Paresh Devidas Salgaonkar

In Yong Lee

Ik-Hwan Han

The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

Compounds and compositions for modulating EGFR mutant kinase activities

Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I). 

Substituted pyrimidine compounds and their use as SYK inhibitors

Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors

The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.

Kinase inhibitors

The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.

Growing community of inventors

Andover, MA, United States of America

Ho-Juhn Song